Literature DB >> 31701059

Community Screening for Diabetes, Hypertension, Nutrition, and Kidney Disease Among Kenyans.

Samuel K Kabinga1, Seth O McLigeyo2, Ahmed Twahir3, John N Ngigi4, Nancy N Wangombe5, Diviner K Nyarera6, Grace W Ngaruiya7, Reuben K Chege5, McDonald O Ogutu8, George M Moturi9.   

Abstract

Entities:  

Year:  2019        PMID: 31701059      PMCID: PMC6829188          DOI: 10.1016/j.ekir.2019.06.015

Source DB:  PubMed          Journal:  Kidney Int Rep        ISSN: 2468-0249


× No keyword cloud information.
Chronic kidney disease (CKD) has emerged as a major public health concern. It was ranked 27th in the list of causes of total number of global deaths in 1990 and rose to 18th position in 2010. Between 1990 and 2013, the mortality from CKD increased by more than 100%.2, 3 Hypertension, diabetes mellitus (DM), and obesity are growing noncommunicable diseases and are important risk factors for CKD. In Kenya, according to Kenya Renal Association (unpublished data), there has been tremendous growth in the number of facilities offering hemodialysis services across the country. The number of hemodialysis units rose from 10 in 2006 to 102 by March 2018, and the number of patients on chronic hemodialysis increased from 300 to 2400 in the same time period. Detection of CKD in earlier stages provides opportunities for treatment, thus slowing CKD progression and reducing the incidence of complications. It is in this context that we carried out the current study.

Methods

We carried out a cross-sectional descriptive analysis of data obtained from community screening for kidney disease during World Kidney Days and through outreach in Kenya from 2011 to 2019. We aimed to document the burden of CKD and the risk factors. This included screening for DM, hypertension, and nutrition, and urinalysis as surrogates for kidney disease. The study population included all individuals who presented themselves for the screening exercise. Data captured included age, sex, county of residence, and personal history of smoking, DM, and hypertension. Family history of CKD, hypertension, and DM was also recorded. Measurements of random blood sugar (RBS), blood pressure, body mass index, and urinalysis by dipstick method were performed. The study was approved by the Kenyatta National Hospital—University of Nairobi Ethics Research Committee, registration number P505/07/2018.

Results

Between 2011 and 2019, a total of 5138 individuals’ screening records were traced and analyzed. As a group, the individuals resided in 24 of the 47 counties of Kenya. Females constituted 53%. About half of the individuals resided in urban and peri-urban counties (Nairobi and Kiambu); the rest resided in rural counties. The youngest person was aged 5 years, and the oldest was aged 102 years. The mean age was 40.89 years, the mode was 30 years, and the median age was 40 years. Almost 5% were active smokers, 8.4% were known diabetics, and 17.5% were known hypertensives. Family history was found in 29.2% for hypertension, 22.3% for DM, and 7% for CKD. When the risk factors for CKD were stratified by sex, cigarette smoking was found to be more prevalent in men (3.6% vs. 1.2%), and hypertension was more prevalent in women (10.9% vs. 6.5%). Further classification by urbanization revealed that rural residents had greater incidence of DM (10.8% vs. 6.3%) and hypertension (21.6% vs. 13.9%; Table 1). Systolic blood pressure of ≤120 mm Hg was recorded in 33.3%, and >150 mm Hg in 20%. Almost 60% of individuals had diastolic blood pressure ≤80 mm Hg, and 20% >90 mm Hg. Half of the individuals who were aged ≥18 years (4712) were underweight (<18.5 kg/m2) or normal weight (18.5–24.9 kg/m2). A third were pre-obese (25.0–29.9 kg/m2), and 28.7% were obese (>30.0 kg/m2), by World Health Organization classification standards. There were 167 (3.4%) individuals whose RBS was >11.0 mmol/L, >50% of whom were known diabetics, 41.6% of whom had a family history of DM, and 44.6% of whom were hypertensive. Of the individuals with RBS levels >11.0 mmol/L, 74 (1.4%) had no prior knowledge of their high blood sugar state. There was an exponential increase in the prevalence of hyperglycemia after the age of 35 years, found in almost 1 in every 5 individuals aged 56–60 years. Those aged >40 years recorded the highest burden of both DM and hypertension. Hypertension and DM were more common among individuals with a higher body mass index. Among the 5138 individuals, 3890 (75.7%) had a urine dipstick test performed, and 12.1% tested positive for proteinuria (+1 to +4).
Table 1

Distribution of smoking history, and personal and family history of diabetes, hypertension, and chronic kidney disease

CharacteristicAllMaleFemaleUrbanRural
Sex5138 (100)2405 (46.8)2730 (53.1)2736 (53)2402 (47)
Smoking history245 (4.8)183 (3.6)62 (1.2)150 (5.5)95 (3.9)
Diabetes mellitus432 (8.4)197 (3.8)235 (4.6)173 (6.3)259 (10.8)
Hypertension898 (17.5)335 (6.5)561 (10.9)378 (13.9)520 (21.6)
Family history of hypertension1498 (29.2)652 (12.7)844 (16.4)945 (34.8)553 (23.0)
Family history of diabetes mellitus1,144 (22.3)533 (10.4)610 (11.9)710 (26.1)434 (18.1)
Family history of chronic kidney disease359 (7.0)176 (3.4)183 (3.6)232 (8.5)127 (5.3)

Values are n (%).

Distribution of smoking history, and personal and family history of diabetes, hypertension, and chronic kidney disease Values are n (%).

Discussion

There was no sex preponderance among the screened individuals. The majority were aged <50 years. There was a significant history of cigarette smoking, and personal history of DM and hypertension, which are known risk factors for CKD. Emphasis on early detection of CKD and secondary prevention, by controlling several well-known risks, are potential cost-effective solutions. An individual with CKD stage 3 is more than 12 times more likely to die from cardiovascular diseases than to progress to end-stage renal disease. Blood pressure control was not satisfactory in our study. High prevalence rates of hypertension have been reported in sub-Saharan African populations, e.g., Benin, 27.9%; Malawi, 53%; Nigeria, about 32.3%; and Tanzania, about 30%. In the West Indies, self-reporting of hypertension was at 28%, and 53.1% actually had hypertension. DM was more prevalent in rural than in urban areas. In India, various studies have found DM in 7%–18%, and hypertension has been reported at prevalence rates of 23.3%–31.2%, higher than those in our study findings. In our study, 8.4% were already known to be diabetic, and an additional 1.4% were newly diagnosed with high levels of RBS. A family history of DM was found in 22.3% of the individuals screened. In other African countries, the prevalence of DM has been reported at 18% in Malawi, 6% in Tanzania, 3% in Benin, and 6% in Nigeria. In East Africa, the prevalence of DM in Uganda and Tanzania has been reported to be 10.1%. In the US, rural dwellers are more likely to have DM and hypertension compared with urban dwellers. This finding supports the fact that hypertension and diabetes are more prevalent in developed nations, with developing countries catching up. In our study, 3.4% had RBS levels above 11.0 mmol/L. A study in Haiti reported about 8.2% of participants whose serum glucose level was >11.0 mmol/L, with 0.14% of these individuals being unaware of a diagnosis of diabetes. The rural residents had more DM and hypertension. Cigarette smoking was more common among men. In a community screening in Nigeria, cigarette smoking was reported in 4.5%. Among urban populations in India, the prevalence of smoking has been reported as 4.7%. These findings are comparable to our study findings but the prevalences are lower than those in reports from the US. About one third of our study individuals were pre-obese, and the rest were obese, comparable to findings from Nigeria. Attempts to identify surrogate measures for the presence of kidney disease at an early stage have included the use of proteinuria, which can be a signal to clinicians to diagnose and confirm the presence of kidney disease at an early stage. In our study, 12.1% of the screened individuals had proteinuria, as measured by dipstick test, which is lower than percentages reported in Nigeria but comparable to those reported from India. In conclusion, our population has a high risk for development of CKD, with rural dwellers having a higher burden of risk. This situation calls for more deliberate efforts to screen and confirm for CKD, and employment of strategies and programs to curb advancement to end-stage renal disease, which might not be manageable in poor economies.

Disclosure

All the authors declared no competing interests.
  9 in total

1.  Identifying High-Risk Individuals for Chronic Kidney Disease: Results of the CHERISH Community Demonstration Project.

Authors:  Nilka Ríos Burrows; Joseph A Vassalotti; Sharon H Saydah; Rebecca Stewart; Monica Gannon; Shu-Cheng Chen; Suying Li; Sarah Pederson; Allan J Collins; Desmond E Williams
Journal:  Am J Nephrol       Date:  2018-11-23       Impact factor: 3.754

2.  Slowing the progression of chronic renal failure: economic benefits and patients' perspectives.

Authors:  Hariprasad S Trivedi; Michael M H Pang; Anne Campbell; Paulette Saab
Journal:  Am J Kidney Dis       Date:  2002-04       Impact factor: 8.860

3.  The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age.

Authors:  B O Eriksen; O C Ingebretsen
Journal:  Kidney Int       Date:  2006-01       Impact factor: 10.612

Review 4.  Evolving importance of kidney disease: from subspecialty to global health burden.

Authors:  Kai-Uwe Eckardt; Josef Coresh; Olivier Devuyst; Richard J Johnson; Anna Köttgen; Andrew S Levey; Adeera Levin
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

Review 5.  Chronic kidney disease: global dimension and perspectives.

Authors:  Vivekanand Jha; Guillermo Garcia-Garcia; Kunitoshi Iseki; Zuo Li; Saraladevi Naicker; Brett Plattner; Rajiv Saran; Angela Yee-Moon Wang; Chih-Wei Yang
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

6.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

Review 7.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

8.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Rafael Lozano; Mohsen Naghavi; Kyle Foreman; Stephen Lim; Kenji Shibuya; Victor Aboyans; Jerry Abraham; Timothy Adair; Rakesh Aggarwal; Stephanie Y Ahn; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Suzanne Barker-Collo; David H Bartels; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Kavi Bhalla; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; Fiona Blyth; Ian Bolliger; Soufiane Boufous; Chiara Bucello; Michael Burch; Peter Burney; Jonathan Carapetis; Honglei Chen; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Diego De Leo; Louisa Degenhardt; Allyne Delossantos; Julie Denenberg; Don C Des Jarlais; Samath D Dharmaratne; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Patricia J Erwin; Patricia Espindola; Majid Ezzati; Valery Feigin; Abraham D Flaxman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Sherine E Gabriel; Emmanuela Gakidou; Flavio Gaspari; Richard F Gillum; Diego Gonzalez-Medina; Yara A Halasa; Diana Haring; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Bruno Hoen; Peter J Hotez; Damian Hoy; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Ganesan Karthikeyan; Nicholas Kassebaum; Andre Keren; Jon-Paul Khoo; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Michael Lipnick; Steven E Lipshultz; Summer Lockett Ohno; Jacqueline Mabweijano; Michael F MacIntyre; Leslie Mallinger; Lyn March; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; John McGrath; George A Mensah; Tony R Merriman; Catherine Michaud; Matthew Miller; Ted R Miller; Charles Mock; Ana Olga Mocumbi; Ali A Mokdad; Andrew Moran; Kim Mulholland; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Kiumarss Nasseri; Paul Norman; Martin O'Donnell; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; David Phillips; Kelsey Pierce; C Arden Pope; Esteban Porrini; Farshad Pourmalek; Murugesan Raju; Dharani Ranganathan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Frederick P Rivara; Thomas Roberts; Felipe Rodriguez De León; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Joshua A Salomon; Uchechukwu Sampson; Ella Sanman; David C Schwebel; Maria Segui-Gomez; Donald S Shepard; David Singh; Jessica Singleton; Karen Sliwa; Emma Smith; Andrew Steer; Jennifer A Taylor; Bernadette Thomas; Imad M Tleyjeh; Jeffrey A Towbin; Thomas Truelsen; Eduardo A Undurraga; N Venketasubramanian; Lakshmi Vijayakumar; Theo Vos; Gregory R Wagner; Mengru Wang; Wenzhi Wang; Kerrianne Watt; Martin A Weinstock; Robert Weintraub; James D Wilkinson; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Paul Yip; Azadeh Zabetian; Zhi-Jie Zheng; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

9.  Community-Based Diabetes Screening and Risk Assessment in Rural West Virginia.

Authors:  Ranjita Misra; Cindy Fitch; David Roberts; Dana Wright
Journal:  J Diabetes Res       Date:  2016-01-12       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.